MT. KISCO, N.Y., Dec. 10, 2015 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) today announced that it has engaged One Equity Research LLC ("One Equity") to provide advisory services and research covering milestone or inflection points in the Company's development.
One Equity has built a robust network that enables them to reach tens of thousands of highly-targeted investors with a high-affinity for undervalued growth companies. ImmuDyne believes this visibility will benefit the Company's growth and vision for the future.
ImmuDyne would point to its Joint Venture with Innate Scientific (the "Innate JV"), formed to market a proprietary line of skin-care products using ImmuDyne's Yeast Beta Glucan and delivery technology, as an example of a high-value deal that would benefit from greater investor visibility. ImmuDyne reiterates that the Innate JV is expected to be accretive to ImmuDyne's 2015 revenues and 2016 income, respectively. The Innate JV is led by a group of experienced online marketers who have partnered with leading global affiliate Marketing Firms to market and sell a line of skin care products based on ImmuDyne's technology.
"We have spent years developing an infrastructure to support the inflection point we believe is coming in 2016. We are excited to finally tell this story to an audience of tens of thousands of investors with the help of One Equity," stated Mark McLaughlin, President and CEO of ImmuDyne.
ImmuDyne has developed proprietary topical and oral delivery technologies, with several new market opportunities. The Company also manufactures and sells yeast beta-1,3/1,6 glucan for oral and topical uses. All of ImmuDyne’s Intellectual Property is protected by patents and/or trade secrets. ImmuDyne has offices located in Mt. Kisco, NY, Tampa, FL, and Florence, KY. Additional information can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
ImmuDyne, Inc. Mark McLaughlin: +1-914-714-8901